Table of Content

1 INTRODUCTION (Page No. - 22)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE 
          FIGURE 1 AMNIOTIC PRODUCTS INDUSTRY SEGMENTATION
           1.3.1 REGIONS CONSIDERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 STAKEHOLDERS 
    1.6 LIMITATIONS 
    1.7 RECESSION IMPACT 
    1.8 SUMMARY OF CHANGES 
2 RESEARCH METHODOLOGY (Page No. - 27)
    2.1 RESEARCH DATA 
          FIGURE 2 AMNIOTIC PRODUCTS MARKET: RESEARCH DESIGN
    2.2 SECONDARY DATA 
           2.2.1 SECONDARY SOURCES
    2.3 PRIMARY DATA 
          FIGURE 3 PRIMARY SOURCES
           2.3.1 KEY DATA FROM PRIMARY SOURCES
           2.3.2 KEY INDUSTRY INSIGHTS
                    FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.4 MARKET SIZE ESTIMATION 
          FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
           2.4.1 GROWTH FORECAST
                    FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
                    FIGURE 7 TOP-DOWN APPROACH
    2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.6 MARKET SHARE ANALYSIS 
    2.7 RESEARCH ASSUMPTIONS 
    2.8 RESEARCH LIMITATIONS 
    2.9 RISK ASSESSMENT 
    2.10 GROWTH RATE ASSUMPTIONS 
    2.11 RECESSION IMPACT ANALYSIS 
3 EXECUTIVE SUMMARY (Page No. - 39)
    FIGURE 9 AMNIOTIC PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 AMNIOTIC PRODUCTS INDUSTRY, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 42)
    4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AMNIOTIC PRODUCTS MARKET 
          FIGURE 13 GROWING TARGET PATIENT POPULATION TO DRIVE MARKET
    4.2 AMNIOTIC PRODUCTS INDUSTRY, BY TYPE 
          FIGURE 14 CRYOPRESERVED AMNIOTIC MEMBRANES SEGMENT TO REGISTER HIGHER CAGR DURING FORECAST PERIOD
    4.3 NORTH AMERICA: MARKET, BY TYPE AND COUNTRY 
          FIGURE 15 US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2022
    4.4 MARKET, BY COUNTRY 
          FIGURE 16 US AND UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 45)
    5.1 INTRODUCTION 
          FIGURE 17 AMNIOTIC PRODUCTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
    5.2 MARKET DYNAMICS 
           5.2.1 DRIVERS
                    5.2.1.1 Growth in target patient population
                                TABLE 1 GLOBAL PREVALENCE OF DIABETES
                    5.2.1.2 Rising incidence of burn injuries and increasing number of traumatic wounds
                    5.2.1.3 Wound care awareness programs and increasing funding for wound care treatment and management
                                TABLE 2 WOUND CARE AWARENESS INITIATIVES
                                TABLE 3 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY NIH UNDER 21ST CENTURY CURES ACT
                                TABLE 4 FUNDING INITIATIVES FROM CORPORATE PARTNERSHIPS IN 2022 (USD MILLION)
                                TABLE 5 FUNDING FROM CORPORATE PARTNERSHIPS IN 2021 (USD MILLION)
                                FIGURE 18 ARTICLES RELATED TO AMNIOTIC PRODUCTS PUBLISHED DURING 2010–2021
                    5.2.1.4 Increasing number of amniotic membrane transplantations
                                TABLE 6 NUMBER OF AMNIOTIC MEMBRANE TRANSPLANTATIONS PERFORMED IN UNIVERSITY EYE HOSPITAL TÜBINGEN, GERMANY
                    5.2.1.5 Increasing number of ophthalmology, cosmetic, and orthopedic surgeries
                    5.2.1.6 Strategic collaborations and partnerships
                    5.2.1.7 Favorable reimbursement policies
                                TABLE 7 MEDICARE ALLOWABLE AMOUNTS (USD)
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Untapped opportunities in emerging economies
                                TABLE 8 STRATEGIC DEVELOPMENTS IN ASIA PACIFIC
                    5.2.2.2 Implementation of 21st Century Cures Act (US)
                    5.2.2.3 Increasing demand for stem cell research and regenerative medicine
                                FIGURE 19 STEM CELL RESEARCH FUNDING FROM 2011 TO 2020
                                TABLE 9 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION)
           5.2.3 CHALLENGES
                    5.2.3.1 Complications and limitations associated with use of amniotic membranes
                    5.2.3.2 Ethical and legal concerns of using amniotic membranes
                    5.2.3.3 High cost of amniotic membrane products
                    5.2.3.4 Competition from alternative therapies
           5.2.4 TRENDS
                    5.2.4.1 Increasing clinical trials for stem cell and chimeric antigen receptor-T cell therapies
                    5.2.4.2 Expanding applications and rising focus on standardization and regulation of amniotic products
    5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 
           5.3.1 REVENUE SHIFT AND REVENUE POCKETS FOR AMNIOTIC PRODUCT MANUFACTURERS
           5.3.2 REVENUE SHIFT IN AMNIOTIC PRODUCTS INDUSTRY
    5.4 PRICING ANALYSIS 
          TABLE 10 PRICES OF AMNIOTIC PRODUCTS
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 20 DIRECT DISTRIBUTION: STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING DEVELOPMENT PHASE
    5.7 ECOSYSTEM ANALYSIS 
           5.7.1 ROLE IN ECOSYSTEM
                    TABLE 11 ROLE OF KEY PLAYERS IN ECOSYSTEM
                    FIGURE 22 KEY PLAYERS IN AMNIOTIC PRODUCTS ECOSYSTEM
    5.8 TECHNOLOGY ANALYSIS 
    5.9 PATENT ANALYSIS 
    5.10 TRADE ANALYSIS 
           TABLE 12 IMPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND)
           TABLE 13 EXPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND)
    5.11 REGULATORY LANDSCAPE 
           5.11.1 NORTH AMERICA
           5.11.2 EUROPE
           5.11.3 EMERGING ECONOMIES
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 14 MARKET: IMPACT OF PORTER’S FIVE FORCES
           5.12.1 INTENSITY OF COMPETITIVE RIVALRY
           5.12.2 BARGAINING POWER OF SUPPLIERS
           5.12.3 BARGAINING POWER OF BUYERS
           5.12.4 THREAT OF SUBSTITUTES
           5.12.5 THREAT OF NEW ENTRANTS
6 AMNIOTIC PRODUCTS MARKET, BY TYPE (Page No. - 69)
    6.1 INTRODUCTION 
    6.2 AMNIOTIC MEMBRANES 
          TABLE 15 AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
           6.2.1 CRYOPRESERVED AMNIOTIC MEMBRANES
                    6.2.1.1 Cryopreserved amniotic membranes to dominate amniotic membranes market during forecast period
                                TABLE 16 CRYOPRESERVED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.2 DEHYDRATED AMNIOTIC MEMBRANES
                    6.2.2.1 Logistical advantages of dehydrated amniotic membranes over cryopreserved amniotic membranes to drive demand
                                TABLE 17 DEHYDRATED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION)
7 AMNIOTIC PRODUCTS MARKET, BY APPLICATION (Page No. - 74)
    7.1 INTRODUCTION 
    7.2 PRIMARY NOTES 
          TABLE 18 AMNIOTIC PRODUCTS INDUSTRY, BY APPLICATION, 2021–2028 (USD MILLION)
    7.3 WOUND CARE 
           7.3.1 RISING INCIDENCE OF ULCERS, TRAUMATIC AND SURGICAL WOUNDS, AND BURNS TO DRIVE MARKET
                    TABLE 19 MARKET FOR WOUND CARE, BY REGION, 2021–2028 (USD MILLION)
    7.4 ORTHOPEDICS 
           7.4.1 BENEFITS OFFERED BY AMNIOTIC PRODUCTS FOR ORTHOPEDIC APPLICATIONS TO DRIVE MARKET
                    TABLE 20 MARKET FOR ORTHOPEDICS, BY REGION, 2021–2028 (USD MILLION)
    7.5 OPHTHALMOLOGY 
           7.5.1 LIGHTWEIGHT, THIN, AND ELASTIC NATURE OF AMNIOTIC MEMBRANES TO DRIVE DEMAND IN OPHTHALMOLOGY
                    TABLE 21 MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION)
    7.6 OTHER APPLICATIONS 
          TABLE 22 ESTIMATED NUMBER OF COLORECTAL CANCER CASES AND DEATHS IN US IN 2020, BY AGE
          TABLE 23 MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
8 AMNIOTIC PRODUCTS MARKET, BY END USER (Page No. - 82)
    8.1 INTRODUCTION 
          TABLE 24 AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    8.2 HOSPITALS & AMBULATORY SURGERY CENTERS 
           8.2.1 INCREASING NUMBER OF SURGICAL PROCEDURES TO DRIVE MARKET
                    TABLE 25 MARKET FOR HOSPITALS & ASCS, BY REGION, 2021–2028 (USD MILLION)
    8.3 OTHER END USERS 
          TABLE 26 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
9 AMNIOTIC PRODUCTS MARKET, BY REGION (Page No. - 87)
    9.1 INTRODUCTION 
          TABLE 27 AMNIOTIC PRODUCTS INDUSTRY, BY REGION, 2021–2028 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 23 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET SNAPSHOT
          TABLE 28 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 29 NORTH AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 30 NORTH AMERICA: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 31 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.1 US
                    9.2.1.1 Growing geriatric population and high prevalence of chronic wounds and diabetes to drive market
                                TABLE 32 US: KEY MACRO INDICATORS
                                TABLE 33 US: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 34 US: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 35 US: AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Rising prevalence of target diseases to drive market
                                TABLE 36 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029
                                TABLE 37 CANADA: KEY MACRO INDICATORS
                                TABLE 38 CANADA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 39 CANADA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 40 CANADA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.2.3 RECESSION IMPACT ON NORTH AMERICA
    9.3 EUROPE 
          TABLE 41 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP)
          TABLE 42 PREVALENCE OF DIABETES IN EUROPE, 2019 VS. 2045
          TABLE 43 EUROPE: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 44 EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 45 EUROPE: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 46 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 Increasing incidence of diabetes to drive market
                                TABLE 47 GERMANY: KEY MACRO INDICATORS
                                TABLE 48 GERMANY: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 49 GERMANY: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 50 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 High prevalence of diabetes activities to drive market
                                TABLE 51 UK: KEY MACRO INDICATORS
                                TABLE 52 UK: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 53 UK: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 54 UK: AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Government support to drive demand for amniotic products
                                TABLE 55 FRANCE: KEY MACRO INDICATORS
                                TABLE 56 FRANCE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 57 FRANCE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 58 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.4 REST OF EUROPE
                    TABLE 59 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP)
                    TABLE 60 REST OF EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 61 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 62 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.3.5 RECESSION IMPACT ON EUROPE
    9.4 ASIA PACIFIC 
          FIGURE 24 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET SNAPSHOT
          TABLE 63 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 64 ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 65 ASIA PACIFIC: MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
          TABLE 66 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Increasing incidence of diabetes and growth in geriatric population to drive market
                                TABLE 67 CHINA: KEY MACRO INDICATORS
                                TABLE 68 CHINA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 69 CHINA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 70 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Growing geriatric population to drive market
                                TABLE 71 JAPAN: KEY MACRO INDICATORS
                                TABLE 72 JAPAN: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 73 JAPAN: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                TABLE 74 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
           9.4.3 REST OF ASIA PACIFIC
                    TABLE 75 REST OF ASIA PACIFIC: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021
                    TABLE 76 REST OF ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 77 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 78 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           9.4.4 RECESSION IMPACT ON ASIA PACIFIC
    9.5 LATIN AMERICA 
           9.5.1 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
                    TABLE 79 LATIN AMERICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021
                    TABLE 80 LATIN AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 81 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 82 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
           9.6.1 GROWTH IN HEALTHCARE INFRASTRUCTURE AND GOVERNMENT INITIATIVES TO DRIVE MARKET
                    TABLE 83 MIDDLE EAST & AFRICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021
                    TABLE 84 MIDDLE EAST & AFRICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 85 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                    TABLE 86 MIDDLE EAST & AFRICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
10 COMPETITIVE LANDSCAPE (Page No. - 123)
     10.1 OVERVIEW 
     10.2 STRATEGIES ADOPTED BY KEY PLAYERS 
             TABLE 87 OVERVIEW OF STRATEGIES ADOPTED BY KEY AMNIOTIC PRODUCT MARKET PLAYERS
     10.3 MARKET SHARE ANALYSIS, 2022 
             TABLE 88 AMNIOTIC PRODUCTS MARKET: DEGREE OF COMPETITION (2022)
     10.4 REVENUE SHARE ANALYSIS, 2022 
             FIGURE 25 AMNIOTIC PRODUCTS INDUSTRY: REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS, 2020–2022
     10.5 COMPANY EVALUATION QUADRANT 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                        FIGURE 26 MARKET: COMPANY EVALUATION MATRIX, 2022
     10.6 SMALL AND MEDIUM-SIZED ENTERPRISE/STARTUP EVALUATION QUADRANT 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 STARTING BLOCKS
             10.6.3 RESPONSIVE COMPANIES
             10.6.4 DYNAMIC COMPANIES
                        FIGURE 27 MARKET: SMALL AND MEDIUM-SIZED ENTERPRISE/ STARTUP EVALUATION MATRIX, 2022
     10.7 COMPETITIVE BENCHMARKING 
             TABLE 89 MARKET: DETAILED LIST OF KEY SMALL AND MEDIUM-SIZED ENTERPRISES/STARTUPS
     10.8 COMPETITIVE SCENARIO 
             10.8.1 PRODUCT LAUNCHES
                        TABLE 90 PRODUCT LAUNCHES
             10.8.2 DEALS
                        TABLE 91 DEALS
             10.8.3 OTHERS
                        TABLE 92 OTHERS
     10.9 COMPANY FOOTPRINT ANALYSIS 
             TABLE 93 COMPANY FOOTPRINT ANALYSIS
             TABLE 94 COMPANY PRODUCT FOOTPRINT
             TABLE 95 COMPANY REGIONAL FOOTPRINT
11 COMPANY PROFILES (Page No. - 135)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     11.1 KEY PLAYERS 
             11.1.1 MIMEDX GROUP, INC.
                        TABLE 96 MIMEDX GROUP, INC.: COMPANY OVERVIEW
                        FIGURE 28 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022)
             11.1.2 SMITH+NEPHEW
                        TABLE 97 SMITH+NEPHEW: COMPANY OVERVIEW
                        FIGURE 29 SMITH+NEPHEW: COMPANY SNAPSHOT (2022)
             11.1.3 ORGANOGENESIS INC.
                        TABLE 98 ORGANOGENESIS INC.: COMPANY OVERVIEW
                        FIGURE 30 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022)
             11.1.4 INTEGRA LIFESCIENCES
                        TABLE 99 INTEGRA LIFESCIENCES: COMPANY OVERVIEW
                        FIGURE 31 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022)
             11.1.5 STRYKER
                        TABLE 100 STRYKER: COMPANY OVERVIEW
                        FIGURE 32 STRYKER: COMPANY SNAPSHOT (2022)
             11.1.6 APPLIED BIOLOGICS
                        TABLE 101 APPLIED BIOLOGICS: COMPANY OVERVIEW
             11.1.7 CELULARITY INC.
                        TABLE 102 CELULARITY INC.: COMPANY OVERVIEW
             11.1.8 CORZA OPHTHALMOLOGY
                        TABLE 103 CORZA OPHTHALMOLOGY: COMPANY OVERVIEW
             11.1.9 LUCINA BIOSCIENCES
                        TABLE 104 LUCINA BIOSCIENCES: COMPANY OVERVIEW
             11.1.10 NEXT BIOSCIENCES
                        TABLE 105 NEXT BIOSCIENCES: COMPANY OVERVIEW
             11.1.11 SKYE BIOLOGICS HOLDINGS, LLC
                        TABLE 106 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW
             11.1.12 SURGENEX
                        TABLE 107 SURGENEX: COMPANY OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 BIOTISSUE
             11.2.2 VENTRIS MEDICAL, LLC
             11.2.3 STIMLABS LLC
             11.2.4 VIVEX BIOLOGICS, INC.
             11.2.5 LIFECELL
             11.2.6 NUVISION BIOTHERAPIES LTD
             11.2.7 GENESIS BIOLOGICS, INC.
             11.2.8 SURGILOGIX
             11.2.9 TIDES MEDICAL
             11.2.10 ORTHOFIX US LLC
             11.2.11 ALLOSOURCE
             11.2.12 MERAKRIS THERAPEUTICS, INC.
             11.2.13 MTF BIOLOGICS
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 172)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS